Oil Shock Ignites Small Caps, Biotech Deal Fever Spreads, and Safety Concerns Slam a Drug Maker

A surge in crude prices following fresh geopolitical tensions sent small-cap energy names sharply higher, while a heavily financed biotech merger fueled deal-driven optimism.

But not all healthcare stocks joined the rally, as safety concerns forced a late-stage trial pause and rattled confidence in one rare-disease drug developer.

Bloomberg is calling Elon Musk's upcoming SpaceX IPO "the biggest listing of ALL TIME."

But here's the thing - most investors will be locked out until AFTER it goes public.

Not you.

I've found a 'backdoor' that lets everyday Americans grab a pre-IPO stake in SpaceX right now.

Click Here for the FREE "SpaceX" Ticker

U.S. stocks were mixed on Monday as markets rebounded from early losses despite heightened geopolitical tensions following U.S. strikes on Iran.

Strength in technology and energy shares lifted the Nasdaq, while broader concerns over potential inflation from surging oil prices kept gains in the S&P 500 more limited.

Paramount Skydance Corp (NASDAQ: PSKY) just completed its $110 billion acquisition of Warner Bros Discovery, picking up HBO, DC Comics, Harry Potter, Game of Thrones, CNN, and one of the deepest content libraries ever assembled.

The deal makes Paramount the most franchise-rich entertainment company on the planet.

It also saddles the company with roughly $79 billion in net debt, the largest in entertainment history.

The Savings Have to Be Real

Paramount is projecting $6 billion in cost savings by merging streaming platforms, combining technology stacks, and consolidating cloud infrastructure.

That target is aggressive, and most of it has to come from non-labor cuts to avoid gutting the content machine that makes these franchises valuable.

You hear $6 billion in savings, and it sounds like a lot. Against $79 billion in debt, it is a starting point, not a solution.

No Safety Net

Paramount is keeping all its cable assets, including CBS, CNN, and TNT. No divestitures, no spinoffs, nothing sold off to lighten the load. Everything stays under one roof.

You can admire the ambition of owning the most valuable franchise library in entertainment. But $79 billion means Paramount has almost no margin for error.

Every decision from here either justifies the bet or exposes the risk.

UniQure NV (NASDAQ: QURE) just hit a wall.

The FDA reviewed the company's lead program for Huntington's disease and concluded that the trial data cannot support a marketing application.

The evidence did not meet the agency's effectiveness standard, leaving UniQure without a clear path to bringing its only meaningful product to market.

One Program, No Backup

UniQure was built around AMT-130. There is no diversified pipeline to fall back on and no second product ready to carry the business forward.

You do not need to understand gene therapy to recognize what happens when a single-product company gets told its only product is not ready.

The Next Meeting Decides the Future

UniQure plans to meet with the FDA in the second quarter to discuss alternative study designs.

That conversation will determine whether the company has a viable path forward or faces years of additional work before it can try again.

If your read on UniQure was built around a near-term approval, that timeline just shattered completely.

Funding, partnerships, and talent retention all get harder after a rejection like this.

The company has to convince everyone that the science still works while navigating a regulatory process that just reset the clock.

Trillions of new dollars have entered the system in recent years.

Gold supply hasn’t changed nearly as fast.

Physical demand remains strong — particularly overseas.

Meanwhile, most investors own gold through ETFs.

If market focus shifts back to physical supply on March 31st…

Select gold stocks could attract renewed attention.

We’ve identified one small company positioned to benefit if that shift occurs.

Get the name & ticker here

Amazon (NASDAQ: AMZN) is investing $21 billion in Spain to expand data centers and AI infrastructure, bringing its total commitment in the country to nearly $40 billion.

Amazon is not just expanding in Europe. It is choosing where to concentrate its power, and Spain just became the answer.

One Country Gets the Keys

Most tech companies spread their European investments across multiple markets.

Amazon is doing the opposite, stacking billions into a single country and calling it the AI epicenter of its European operations.

You think about why Spain, and the answer is likely a mix of energy access, government cooperation, and geography.

When a company commits $40 billion to one location, the relationship between that company and that country becomes deeply structural.

Infrastructure Is the Real Product

Amazon Web Services already generates a massive share of the company's profit.

Every new data center expands the capacity to sell cloud and AI services to European businesses, governments, and developers.

If your understanding of Amazon is still built around cardboard boxes, the Spain investment tells a very different story.

The fastest-growing part of this company runs on servers, not warehouses.

Scale That Is Hard to Reverse

At $40 billion total, Amazon's presence in Spain becomes nearly impossible to unwind. You rarely see a company move this aggressively to lock down an entire region's cloud and AI future.

For Amazon, Spain is not the story. It is the foundation for owning Europe's next decade of enterprise technology.

👉 Click here to get our closing report to your cell for free!

Battalion Oil Corp [BATL] $11.74 (+112.68%)

Battalion Oil surged as crude prices spiked on escalating Middle East tensions, prompting investors to pile into small-cap exploration and production names leveraged to oil.

Rallybio Corporation [RLYB] $10.97 (+45.49%)

Rallybio jumped after announcing a merger with Candid Therapeutics alongside a $505 million oversubscribed financing to advance its autoimmune pipeline.

Astrana Health Inc [ASTH] $26.34 (+29.56%)

Astrana Health climbed after delivering a massive earnings beat, with EPS of $0.54 crushing estimates and revenue topping forecasts.

Aardvark Therapeutics Inc [AARD] $5.47 (-56.20%)

Aardvark plunged after pausing its Phase 3 trial of ARD-101 due to reversible cardiac safety findings, raising fresh concerns about the drug’s risk profile.

uniQure N.V. [QURE] $10.50 (-32.82%)

uniQure tumbled after the FDA said existing trial data were insufficient to support approval of its Huntington’s gene therapy and recommended an additional controlled study.

Aerovironment Inc [AVAV] $208.32 (-17.42%)

AeroVironment fell sharply after reports that the Pentagon is reopening bidding on a $1.4 billion Space Force contract, threatening a major portion of its backlog and prompting analyst downgrades.

Political transitions historically increase uncertainty—and this cycle is no exception.

Tariff expansion is reviving crash-risk conversations across Wall Street.

Asset protection strategies are gaining attention as volatility accelerates.

Ignoring structural risk has consequences during regime shifts.

Awareness precedes action. No guarantees are implied.

This content is not a recommendation to buy or sell.

Download the FREE Presidential Transition Guide now.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.